Pramipexole Dihydrochloride(pram ah pex’ ole)
Mirapex, Mirapex ERDNC
PREGNANCY CATEGORY C
Drug Classes
Antiparkinsonian
Dopamine receptor agonist
Therapeutic Actions
Stimulates dopamine receptors in the striatum, leading to decrease in parkinsonian symptoms thought to be related to low dopamine levels.
Indications
Treatment of the signs and symptoms of idiopathic Parkinson disease
Treatment of moderate to severe primary restless legs syndrome (Mirapex)
Unlabeled use: Treatment of fibromyalgia
Contraindications and Cautions
Contraindicated with hypersensitivity to pramipexole.
Use cautiously with symptomatic hypotension, impaired renal function, pregnancy, lactation.
Available Forms
Tablets—0.125, 0.25, 0.5, 0.75, 1, 1.5 mg; ER tabletsDNC—0.375, 0.75, 1.5, 2.25, 3, 3.75, 4.5 mg
Dosages
Adults
Parkinson disease: Increase dosage gradually from a starting dose of 0.125 mg PO tid for 1 wk; wk 2—0.25 mg PO tid; wk 3—0.5 mg PO tid; wk 4—0.75 mg PO tid; wk 5—1 mg PO tid; wk 6—1.25 mg PO tid; wk 7—1.5 mg PO tid. Once levels are established, ER tablets may be used for once-a-day dosing. If used in combination with levodopa, consider levodopa dose reduction.
Restless leg syndrome: Initially, 0.125 mg/day PO taken 2–3 hr before bedtime; dose may be increased every 4–7 days, if needed, to 0.25 mg/day and maximum of 0.5 mg/day.
Pediatric patients
Safety and efficacy not established.
Patients with renal impairment
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
